Macrophage-derived selenium-loaded nanoparticle extracellular vesicles, their preparation methods and applications
By preparing and modifying extracellular vesicles of selenium-loaded nanoparticles derived from macrophages, the problems of insufficient targeting and anti-inflammatory effects of existing drugs in the lungs were solved, achieving both effective treatment and safety for acute lung injury.
Patent Information
- Application Number
- CN202611387595.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-09-08
- Publication Date
- 2026-11-17
AI Technical Summary
Existing drugs for treating acute lung injury have poor targeting of the inflamed areas of the lungs, are difficult to effectively remove intracellular reactive oxygen species, have limited anti-inflammatory effects and significant side effects, and are difficult to balance therapeutic efficacy and drug safety.
Selenium-loaded nanoparticle extracellular vesicles derived from macrophages were prepared. Selenium nanoparticles were synthesized through biomineralization and modified with cationic and anionic polysaccharides to form extracellular vesicles derived from macrophages. These vesicles can target the site of lung inflammation and be fully taken up by macrophages, clearing ROS and regulating macrophage polarization.
It significantly improves lung function, reduces inflammatory response, and reprograms M1 macrophages to M2 phenotype polarization, providing a safe and effective intervention for acute lung injury and alleviating pathological damage to lung tissue.
Smart Images

Figure CN123101698A_ABST
Abstract
Description
Technical Field
[0001] This application belongs to the field of biomedical technology, and more specifically, relates to extracellular vesicles of selenium-loaded nanoparticles derived from macrophages, their preparation methods, and applications. Background Technology
[0002] Acute lung injury (ALI) is a severe pulmonary syndrome characterized by widespread inflammatory cell infiltration, increased vascular permeability, and decreased lung function. Excessive production of reactive oxygen species (ROS) is a core element in the development and progression of ALI. Excessive ROS not only directly damages cell structure but also activates pro-inflammatory signaling pathways, inducing immune cell infiltration, abnormal macrophage polarization, and the massive release of pro-inflammatory factors. This triggers and amplifies the inflammatory cascade, disrupts the alveolar-capillary barrier, and ultimately leads to pulmonary edema and respiratory dysfunction.
[0003] Currently, clinical treatment primarily relies on supportive therapies such as mechanical ventilation, fluid management, and anti-infection measures, lacking highly specific and effective drug intervention options. While glucocorticoids and nonsteroidal anti-inflammatory drugs (NSAIDs) are used, their application is limited due to significant side effects: although glucocorticoids can broadly inhibit the release of inflammatory factors and reduce inflammatory responses, long-term or high-dose use can cause immunosuppression, increased risk of secondary infections, glucose metabolism disorders, osteoporosis, and gastrointestinal complications; NSAIDs exert their anti-inflammatory effects by inhibiting cyclooxygenase and reducing prostaglandin synthesis, but they also carry risks such as gastrointestinal mucosal damage, gastrointestinal bleeding, kidney damage, and adverse cardiovascular events.
[0004] Therefore, it is of great significance to develop drugs that are highly effective, low in toxicity, have active targeting capabilities, and can treat acute lung injury. Summary of the Invention
[0005] In view of the shortcomings of the prior art, the purpose of this application is to provide extracellular vesicles of selenium-loaded nanoparticles derived from macrophages, their preparation methods and applications, aiming to solve the problems of existing drugs for treating acute lung injury, such as poor targeting of lung inflammation sites, difficulty in effectively clearing intracellular reactive oxygen species, limited anti-inflammatory effects and significant side effects, and difficulty in balancing therapeutic efficacy and drug safety.
[0006] In a first aspect, this application provides a macrophage-derived selenium-loaded nanoparticle extracellular vesicle, including macrophage-derived extracellular vesicles and selenium nanoparticles synthesized through biomineralization encapsulated in the extracellular vesicles; the surface of the extracellular vesicles is further modified with cationic polysaccharides and anionic polysaccharides.
[0007] Preferably, the macrophages mentioned above are any one of the following: macrophages derived from human peripheral blood mononuclear cells, macrophages derived from human mononuclear cell lines, macrophages derived from mouse bone marrow, and mouse mononuclear macrophage cell lines.
[0008] Preferably, the above-mentioned cationic polysaccharide is chitosan or a derivative thereof.
[0009] Preferably, the anionic polysaccharide is hyaluronic acid.
[0010] Preferably, the extracellular vesicles of the selenium-loaded nanoparticles derived from macrophages have a particle size of 200-400 nm.
[0011] Secondly, this application provides a method for preparing the above-mentioned extracellular vesicles of selenium-loaded nanoparticles derived from macrophages, comprising the following steps: S1. Macrophages were co-incubated with a culture medium containing selenium source. Selenium nanoparticles were synthesized in the macrophages through biomineralization. Then, apoptosis was induced by ultraviolet irradiation. Differential centrifugation was used to obtain macrophage-derived extracellular vesicles containing selenium nanoparticles. S2. The macrophage-derived extracellular vesicles coated with selenium nanoparticles are sequentially mixed with cationic polysaccharide solution and anionic polysaccharide solution and incubated, so that the cationic polysaccharide and anionic polysaccharide are sequentially modified onto the surface of the macrophage-derived extracellular vesicles, and the macrophage-derived selenium nanoparticle-loaded extracellular vesicles are collected.
[0012] Preferably, in step S1, the selenium source is one or more of sodium selenite, sodium selenate, selenium dioxide, selenomethionine, selenocysteine, methylselenocysteine, selenourea, sodium selenosulfate, selenoacetic acid, and selenourea.
[0013] Preferably, in step S1, the concentration of the selenium source is 0.05~0.5 mmol / L.
[0014] Preferably, in step S1, the concentration of the macrophages is 1×10⁻⁶. 7 Cells / mL ~ 1×10 8 per mL.
[0015] Preferably, in step S1, the co-incubation time is 8-12 hours.
[0016] Preferably, in step S1, the differential centrifugation operation is as follows: centrifuge at 1000~2000 rpm for 5~10 min, take the supernatant and centrifuge at 12000~15000 rpm for 15~20 min, collect the precipitate, and thus obtain the macrophage-derived extracellular vesicles encapsulated with selenium nanoparticles.
[0017] Preferably, in step S2, the mass ratio of the macrophage-derived extracellular vesicles coated with selenium nanoparticles to cationic polysaccharides and anionic polysaccharides is (0.5~2):(2~8):(1~4).
[0018] Preferably, in step S2, the collection conditions are: collection with a centrifugal force of 10,000 to 12,000 rpm.
[0019] Thirdly, this application provides a medicament for treating acute lung injury, the medicament comprising the aforementioned macrophage-derived selenium-loaded nanoparticle extracellular vesicles.
[0020] In summary, the technical solutions conceived in this application have the following main technical advantages compared with the prior art: (1) The extracellular vesicles of selenium nanoparticles derived from macrophages provided in this application include extracellular vesicles derived from macrophages and selenium nanoparticles synthesized through biomineralization encapsulated in the extracellular vesicles; the surface of the extracellular vesicles is also modified with cationic polysaccharides and anionic polysaccharides. The extracellular vesicles of selenium nanoparticles derived from macrophages have good biocompatibility, can effectively target the site of lung inflammation and be fully taken up by macrophages, so that the selenium nanoparticles and vesicle contents accumulate in the site of lung inflammation, effectively clearing intracellular ROS, reducing inflammatory response, improving antioxidant level, reprogramming M1 macrophages to M2 phenotype polarization, and synergistically breaking the vicious cycle of oxidative stress and inflammatory response, providing a safe and effective intervention for acute lung injury.
[0021] (2) The macrophage-derived selenium-loaded nanoparticle extracellular vesicles (Se@EVs-CS / HA) provided in this application have a synergistic effect among their components, which can exert anti-inflammatory, antioxidant and tissue repair effects in acute lung injury, significantly improve lung function, reduce inflammatory response, reprogram the polarization phenotype of macrophages, reduce pathological damage to lung tissue, and achieve the best therapeutic effect. Attached Figure Description
[0022] Figure 1 Structural characterization of Se@EVs, Se@EVs-CS, and Se@EVs-CS / HA prepared for embodiments of this application; wherein content a, content b, and content c are TEM images, hydration particle size, and zeta potential, respectively; Figure 2 The uptake of Se@EVs-CS / HA prepared for the embodiments of this application by macrophages; wherein content a is a flow cytometry histogram and content b is a quantitative analysis graph; Figure 3 The effect of Se@EVs-CS / HA prepared for the embodiments of this application on the scavenging of intracellular ROS in MLE-12 cells; wherein content a is a flow cytometry histogram and content b is a quantitative analysis of the relative content of intracellular ROS; Figure 4 The effect of Se@EVs-CS / HA prepared for the embodiments of this application on the scavenging of intracellular ROS in RAW264.7 cells; wherein content a is a flow cytometry histogram and content b is a quantitative analysis of the relative content of intracellular ROS; Figure 5 The effects of Se@EVs-CS / HA prepared for the embodiments of this application on inflammatory factors in MLE-12 cells; wherein content a, content b, and content c are the mRNA levels of IL-β, IL-6, and Arg-1, respectively; Figure 6 The effects of Se@EVs-CS / HA prepared for the embodiments of this application on inflammatory factors in RAW264.7 cells; wherein content a, content b, content c, and content d are the mRNA levels of IL-β, IL-6, TNF-α, and Arg-1, respectively; Figure 7 The effect of preparing Se@EVs-CS / HA polarized M1 macrophages as described in this application embodiment on the M2 type; wherein content a, content b, and content c are respectively flow cytometry dual fluorescence scatter plot, CD80 + The proportion of macrophages, CD206 + The proportion of macrophages; Figure 8 The effect of Se@EVs-CS / HA prepared for the embodiments of this application on improving lung function in ALI mice; wherein content a, content b, content c, content d, content e, content f, content g, content h, content i, and content j are Penh, PAU, EEP, TB, MVb, TVb, f, PIF, Ti, and Te, respectively; Figure 9 The efficacy of Se@EVs-CS / HA prepared for treating ALI mice in this application embodiment; wherein content a is the change in mouse body weight during treatment, and content b and content c are the lung-to-body ratio, HE staining structure of lung tissue, and pathological damage score of lung tissue after treatment, respectively; Figure 10 Lung tissue pathological damage score of Se@EVs-CS / HA prepared for the embodiments of this application after treatment of ALI mice; Figure 11 The mRNA expression levels of inflammatory factors in lung tissue of mice treated with Se@EVs-CS / HA prepared for the embodiments of this application; wherein content a, content b, and content c are the contents of pro-inflammatory factors TNF-α, IL-1β, and IL-6, respectively, and content d is the content of anti-inflammatory factor IL-10; Figure 12The mRNA expression levels of antioxidant enzymes in lung tissue of ALI mice after treatment with Se@EVs-CS / HA prepared for the embodiments of this application; wherein content a, content b, and content c are the contents of antioxidant enzymes SOD1, SOD2, and CAT, respectively; Figure 13 Polarization of macrophages in lung tissue of mice treated with Se@EVs-CS / HA prepared for the embodiments of this application; In all the figures, the same reference numerals are used to indicate the same degree of significance, wherein: This means p < 0.05. This means p < 0.01. This means p < 0.001. p < 0.0001, ns represents no statistical difference. Detailed Implementation
[0023] To make the objectives, technical solutions, and advantages of this application clearer, the following detailed description is provided in conjunction with the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are merely illustrative and not intended to limit the scope of this application.
[0024] In the description of this application, it should be understood that the term "and / or" describes a relationship between related objects, indicating that three relationships can exist. For example, A and / or B can represent: A existing alone, A and B existing simultaneously, or B existing alone. The symbol " / " in this document indicates that the related objects are in an "or" relationship; for example, A / B means A or B.
[0025] In the description of the embodiments in this application, the words "exemplary" or "for example" are used to indicate that they are examples, illustrations, or descriptions. Any embodiment or design that is described as "exemplary" or "for example" in the embodiments of this application should not be construed as being more preferred or advantageous than other embodiments or design options. Specifically, the use of the words "exemplary" or "for example" is intended to present the relevant concepts in a specific manner.
[0026] In the description of the embodiments in this application, unless otherwise stated, "multiple" means two or more.
[0027] This application provides extracellular vesicles containing selenium nanoparticles derived from macrophages, which include extracellular vesicles derived from macrophages and selenium nanoparticles synthesized through biomineralization encapsulated in the extracellular vesicles; the surface of the extracellular vesicles is also modified with cationic polysaccharides and anionic polysaccharides.
[0028] In some embodiments, the macrophages mentioned above are any one of the following: macrophages derived from human peripheral blood mononuclear cells, macrophages derived from human mononuclear cell lines (such as THP-1 cell line, U937 cell line, etc.), macrophages derived from mouse bone marrow, and mouse mononuclear macrophage cell lines (such as RAW264.7 cell line, J774A.1 cell line, P388D1 cell line, etc.).
[0029] In some embodiments, the above-mentioned cationic polysaccharide is chitosan or its derivative, preferably chitosan.
[0030] In some embodiments, the anionic polysaccharide is hyaluronic acid.
[0031] In some embodiments, the surface of the extracellular vesicles is modified with chitosan and hyaluronic acid sequentially from the inside out.
[0032] In some embodiments, the extracellular vesicles of the macrophage-derived selenium-loaded nanoparticles have a particle size of 200-400 nm.
[0033] On the other hand, this application also provides a method for preparing the above-mentioned macrophage-derived selenium-loaded nanoparticle extracellular vesicles, comprising the following steps: S1. Macrophages were co-incubated with a culture medium containing selenium source. Selenium nanoparticles were synthesized in the macrophages through biomineralization. Then, apoptosis was induced by ultraviolet irradiation. Differential centrifugation was used to obtain macrophage-derived extracellular vesicles containing selenium nanoparticles. S2. The macrophage-derived extracellular vesicles coated with selenium nanoparticles are sequentially mixed with cationic polysaccharide solution and anionic polysaccharide solution and incubated, so that the cationic polysaccharide and anionic polysaccharide are sequentially modified onto the surface of the macrophage-derived extracellular vesicles, and the above-mentioned macrophage-derived selenium nanoparticle-loaded extracellular vesicles are collected.
[0034] In some embodiments, in step S1, the selenium source is one or more of sodium selenite, sodium selenate, selenium dioxide, selenomethionine, selenocysteine, methylselenocysteine, selenourea, sodium selenosulfate, selenoacetic acid, and selenourea.
[0035] In some embodiments, in step S1, the concentration of the selenium source is 0.1~0.25 mmol / L. When the concentration of the selenium source is too high, the activity of macrophages will decrease significantly, affecting the synthesis of selenium nanoparticles and the subsequent preparation of extracellular vesicles.
[0036] In some embodiments, in step S1, the concentration of the macrophages is 1 × 10⁻⁶. 7 Cells / mL ~ 1×10 8 per mL.
[0037] In some implementations, the co-incubation time in step S1 is 8-12 hours.
[0038] In some embodiments, in step S1, the differential centrifugation operation is as follows: centrifuge at 1000~2000 rpm for 5~10 min, take the supernatant and centrifuge at 12000~15000 rpm for 15~20 min, collect the precipitate, and thus obtain the above-mentioned macrophage-derived extracellular vesicles encapsulating selenium nanoparticles.
[0039] In some embodiments, in step S2, the mass ratio of the macrophage-derived extracellular vesicles coated with selenium nanoparticles to cationic polysaccharides and anionic polysaccharides is (0.5~2):(2~8):(1~4).
[0040] In some implementations, in step S2, the collection conditions are: collection with a centrifugal force of 10,000 to 12,000 rpm.
[0041] This application also provides a medicament for treating and / or preventing acute lung injury, comprising the above-mentioned macrophage-derived selenium-loaded nanoparticle extracellular vesicles.
[0042] It is understood that the aforementioned drugs may consist solely of extracellular vesicles of selenium-loaded nanoparticles derived from macrophages, or may be formulated into suitable dosage forms together with pharmaceutically acceptable carriers, excipients, or diluents. Exemplary carriers include, but are not limited to, solvents, dispersion media, oil-in-water or water-in-oil emulsions, aqueous compositions, liposomes, microbeads, and microparticles. This application does not specifically limit the dosage form of the aforementioned drugs, which may include, but is not limited to, injections, suspensions, or lyophilized powders; the route of administration may be selected from, but is not limited to, intravenous administration.
[0043] It should be understood that, unless otherwise specified, the experimental methods used in the following examples are conventional methods. Unless otherwise specified, the materials and reagents used in the following examples are commercially available.
[0044] The following is an example: Example 1: Preparation of extracellular vesicles of selenium-loaded nanoparticles derived from macrophages 1. Experimental Procedure 1) Seed macrophages in DMEM medium and adjust the cell concentration to 1×10⁶ cells / mL. 7Cells were cultured at a concentration of 1 / mL and a final concentration of 0.25 mM Na₂SeO₃ solution was added. The cells were incubated at 37°C for 12 h, then placed in a 10 cm diameter cell culture dish and irradiated under UV light for 1 h. Following this, the cells were placed in a sterile cell culture incubator at 37°C and 5% CO₂ for 12 h. Apoptotic macrophages were then isolated. Cell debris was removed by centrifugation at 1500 rpm for 5 min, and the supernatant was collected. The supernatant was then centrifuged at 13000 rpm for 15 min, and the precipitate was collected to obtain Se@EVs.
[0045] 2) Prepare a chitosan (CS) solution with a final concentration of 4 mg / mL using PBS, and stir overnight to ensure complete dissolution of CS. Prepare a hyaluronic acid (HA) solution with a final concentration of 2 mg / mL using PBS, and stir overnight to ensure complete dissolution of HA.
[0046] 3) Place Se@EVs in the above CS solution at a mass ratio of 1:4, react at room temperature for 90 min using a multi-functional rotary shaker, then centrifuge at 12000 rpm for 5 min, collect the precipitate, and wash three times with PBS solution to obtain Se@EVs-CS. Then place Se@EVs-CS in the above HA solution at a mass ratio of 2:1, react at room temperature for 60 min using a multi-functional rotary shaker, then centrifuge at 12000 rpm for 5 min, collect the precipitate, and wash three times with PBS solution to obtain Se@EVs-CA / HA.
[0047] 2. Experimental Results TEM results showed that Se@EVs were spherical, surrounded by a membrane structure, exhibiting a membrane-like vesicle structure consistent with the characteristics of extracellular vesicles. This indicates that the synthesized selenium nanoparticles were encapsulated within vesicles and secreted into cells as extracellular vesicles. The diameter of Se@EVs was approximately 50–100 nm. Figure 1 Content a); The diameter of the Se@EVs-CS group modified by CS increased to about 150 nm. Figure 1 Content a); The diameter of the Se@EVs-CS / HA group modified with CS and HA increased to about 200 nm. Figure 1 Content a) indicates that CS and HA were successfully modified on the Se@EVs surface.
[0048] The hydrated particle size and Zeta potential of Se@EVs, Se@EVs-CS, and Se@EVs-CS / HA were determined using a dynamic light scattering particle size analyzer (DLS). The average hydrated particle sizes were 169.73 nm, 247.9 nm, and 339.67 nm, respectively. Figure 1Content b), the hydrated particle size of Se@EVs-CS / HA is significantly larger than that of Se@EVs and Se@EVs-CS, further confirming that CS and HA were successfully modified on the surface of Se@EVs. Furthermore, the hydrated particle size is larger than the particle size measured by TEM, which is due to the formation of a hydration layer in the aqueous solution by Se@EVs.
[0049] The Zeta potentials of Se@EVs, Se@EVs-CS, and Se@EVs-CS / HA were -17.32 mV, 9.99 mV, and -10.29 mV, respectively. Figure 1 Content c), the change in Zeta potential further confirms that the positively charged CS was successfully coated on the negatively charged Se@EVs surface, and the negatively charged HA was modified on the positively charged Se@EVs-CS surface.
[0050] Example 2: Targeting of macrophages by Se@EVs-CS / HA 1. Experimental Methods The Se@EVs and Se@EVs-CS / HA synthesized in Example 1 were labeled with the fluorescent dye DID and incubated with RAW264.7 macrophages at 37°C in a 5% CO2 incubator for 30 min in the dark. Then, the proportion of DID-positive cells in macrophages was detected by flow cytometry. The Ctrl group consisted of unstained macrophages treated with an equal volume of PBS and served as a fluorescence background reference.
[0051] 2. Experimental Results The flow cytometry histogram shows that ( Figure 2 Content a), the fluorescence signal of the Ctrl group was the weakest, the Se@EVs group showed a clear uptake peak, and the fluorescence peak of the Se@EVs-CS / HA group shifted further to the right, indicating a significant increase in uptake. Quantitative analysis showed ( Figure 2 (Content b) The average fluorescence intensity of the Se@EVs-CS / HA group was approximately twice that of the Se@EVs group, and both were significantly higher than those of the Ctrl group.
[0052] Example 3: Se@EVs-CS / HA scavenging intracellular ROS 1. Experimental Methods 1) RAW264.7 macrophages and MLE-12 lung epithelial cells were seeded in 6-well plates and cultured with 100 ng / mL lipopolysaccharide (LPS) for 24 h. Subsequently, PBS, equal amounts of EVs, Se@EVs, and Se@EVs-CS / HA were added for treatment, resulting in the LPS group, EVs group, Se@EVs group, and Se@EVs-CS / HA group, respectively. The final Se concentration in the Se@EVs group and Se@EVs-CS / HA group was 5 μg / mL. All groups were incubated for 4 h. After incubation, the cells were co-incubated with the DCFH-DA fluorescent probe for 30 min, and intracellular ROS levels were detected by flow cytometry. The Ctrl group consisted of normal cells that were not treated with LPS or any other materials, but were given an equal volume of PBS and incubated with the DCFH-DA fluorescent probe; these were used to determine basal ROS levels.
[0053] 2. Experimental Results Flow cytometry histograms of MLE-12 lung epithelial cells and RAW264.7 macrophages showed ( Figure 3 Content a. Figure 4 Content a), compared to the Ctrl group, the fluorescence peaks in the LPS group were significantly shifted to the right, and the ROS level was significantly increased; compared to the LPS group, the fluorescence peaks in the EVs, Se@EVs, and Se@EVs-CS / HA treatment groups were all shifted to the left, with the peak position of the Se@EVs-CS / HA group being closest to the control group. Quantitative analysis showed that ( Figure 3 Content b Figure 4 Content b), Se@EVs-CS / HA can effectively reduce LPS-induced elevated ROS levels, and its ROS scavenging effect is significantly better than that of the EVs and Se@EVs groups.
[0054] Example 4: Se@EVs-CS / HA downregulates the expression of inflammatory factors 1. Experimental Methods 1) RAW264.7 macrophages and MLE-12 lung epithelial cells were seeded into 6-well plates and cultured with 100 ng / mL lipopolysaccharide (LPS) for 24 h. Subsequently, PBS, equal amounts of EVs, Se@EVs, and Se@EVs-CS / HA were added for incubation, resulting in the LPS group, EVs group, Se@EVs group, and Se@EVs-CS / HA group, respectively. The final Se concentration in the Se@EVs and Se@EVs-CS / HA groups was 5 μg / mL. All groups were incubated for a total of 12 h. The Ctrl group consisted of normal cells that were not treated with LPS or any other materials and were only incubated with an equal volume of PBS. After incubation, the mRNA expression levels of inflammatory factors in the cells were detected using qPCR.
[0055] 2. Experimental Results In MLE-12 cells, compared with the LPS group, the mRNA levels of pro-inflammatory factors IL-1β and IL-6 in EVs, Se@EVs, and Se@EVs-CS / HA groups were significantly decreased. Figure 5 Content a. Figure 5 Content b), the level of anti-inflammatory factor Arg-1 mRNA was significantly increased ( Figure 5 Content c). Among them, Se@EVs-CS / HA showed significantly better effects in regulating IL-6 and Arg-1 than other groups.
[0056] In RAW264.7 cells, compared with the LPS group, the mRNA levels of pro-inflammatory factors IL-1β, IL-6, and TNF-α were significantly reduced in the EVs, Se@EVs, and Se@EVs-CS / HA groups. Figure 6 Content a. Figure 6 Content b Figure 6 Content c), the level of anti-inflammatory factor Arg-1 mRNA was significantly increased ( Figure 6 (Content d). Among them, Se@EVs-CS / HA showed the best effect in regulating IL-1β, TNF-α, and Arg-1.
[0057] Example 5: Se@EVs-CS / HA reverse polarizes M1 macrophages to M2 type. 1. Experimental Methods Macrophages were incubated using the method described in Example 4 to obtain the Ctrl group, LPS group, EVs group, Se@EVs group, and Se@EVs-CS / HA group. Cells from each treatment group were collected and then co-incubated with anti-CD80 antibody and anti-CD206 antibody for 30 min, respectively. The expression levels of CD80 and CD206 in macrophages were detected by flow cytometry.
[0058] 2. Experimental Results Flow cytometry dual fluorescence scatter plot shows that ( Figure 7 Content a), compared to the Ctrl group, CD80 in the LPS group + The significantly increased proportion of cells indicates that LPS successfully polarized M0 macrophages into M1 macrophages. Compared to the LPS group, the addition of EVs, Se@EVs, and Se@EVs-CS / HA resulted in a significant increase in CD80 levels in macrophages. + The proportion of cells decreased significantly ( Figure 7 Content b), CD206 + The proportion of cells increased significantly ( Figure 7Content c), the results show that Se@EVs-CS / HA can significantly downregulate the LPS-induced M1 pro-inflammatory phenotype marker (CD80) and upregulate the M2 anti-inflammatory phenotype marker (CD206), indicating that it can effectively reverse LPS-driven macrophage inflammatory polarization, inhibit the M1 pro-inflammatory phenotype and promote polarization to the M2 anti-inflammatory phenotype.
[0059] Example 6: Se@EVs-CS / HA improves lung function in ALI mice 1. Experimental Methods Male C57BL-6J mice were randomly divided into five groups: normal control group (Ctrl), LPS exposure group (LPS), EVs treatment group (EVs), Se@EVs-CS treatment group (Se@EVs-CS), and Se@EVs-CS / HA treatment group (Se@EVs-CS / HA).
[0060] In the Ctrl group, each mouse received an intraperitoneal injection of 200 μL of saline, followed by a tail vein injection of saline 6 hours later. In the LPS group, each mouse received an intraperitoneal injection of 200 μL of LPS at a dose of 8 mg / kg to establish a mouse ALI model, followed by a tail vein injection of saline 6 hours later. In the EVs group, each mouse received an intraperitoneal injection of 200 μL of LPS at a dose of 8 mg / kg, followed by a tail vein injection of 10 mg / kg of EVs (10 mg of the test substance per kg of mouse body weight) 6 hours later. In the Se@EVs group, each mouse received an intraperitoneal injection of 200 μL of LPS at a dose of 8 mg / kg, followed by a tail vein injection of 10 mg / kg of Se@EVs 6 hours later. In the Se@EVs-CS / HA group, each mouse received an intraperitoneal injection of 200 μL of LPS at a dose of 8 mg / kg, followed by a tail vein injection of 10 mg / kg of Se@EVs-CS / HA 6 hours later. Lung function was measured in mice using a whole-body plethysmography (WBP) system 24 hours after treatment.
[0061] 2. Experimental Results WBP test results indicate that ( Figure 8Compared to the Ctrl group, the LPS group showed a significant decrease in lung function, indicating the successful establishment of the mouse ALI model. Compared to the LPS group, lung function was alleviated in all treatment groups, with the Se@EVs-CS / HA treatment group showing the best therapeutic effect, characterized by decreased airway narrowing index (Penh), apnea (PAU), end-expiratory apnea time (EEP), inspiratory time (Ti), expiratory time (Te), and tidal volume (TVb); and increased end-expiratory apnea ratio (TB), minute ventilation (MVb), respiratory rate (f), and maximum inspiratory flow rate (PIF), indicating a synergistic effect among the components of Se@EVs-CS / HA. These results demonstrate that Se@EVs-CS / HA can alleviate LPS-induced lung function injury.
[0062] Example 7: Se@EVs-CS / HA improves body weight, lung-to-body ratio, and lung tissue damage in ALI mice. 1. Experimental Methods The intervention treatment was the same as in Example 6, and the weight of the mice was recorded at 0, 6, 12, 18 and 24 hours after the intervention treatment. Then the mice were sacrificed, and lung tissue was collected and the lung-to-body ratio was calculated according to the following formula: Lung-to-body ratio = (Lung weight of mouse / Body weight of mouse) × 100%. The lung tissue was then fixed, embedded, sectioned, and stained with HE to observe its pathological structure. The pathological score was performed according to the Smith scoring method shown in Table 1.
[0063] Table 1 Smith Scoring Method
[0064] 2. Experimental Results The results showed that the weight change in mice in the Se@EVs-CS / HA treatment group was better than that in other treatment groups and significantly better than that in the LPS group. Figure 9 Content a), the lung-to-body ratio was significantly lower than that of other treatment groups ( Figure 9 Content b) confirmed the synergistic effect among components in Se@EVs-CS / HA. HE staining results showed that ( Figure 9 Content c) In the Ctrl group, the alveolar structure of mice was relatively intact, with no exudation in the alveolar cavities, no thickening of the alveolar interstitium, and no positive cell infiltration. Compared with the Ctrl group, the LPS group showed significant lung tissue damage, characterized by thickening of the lung septa, destruction of alveolar structure, extensive infiltration of inflammatory cells, fusion of alveolar cavities, and a large amount of exudate. After treatment with EVs, Se@EVs, and Se@EVs-CS / HA, respectively, the lung interstitium of mice thinned, exudate decreased, alveolar structure tended to normalize, and inflammatory cell infiltration decreased.
[0065] Pathological damage scoring results showed ( Figure 10The lung tissue pathological damage score of the Se@EVs-CS / HA treatment group was significantly lower than that of the LPS group and other treatment groups, indicating that Se@EVs-CS / HA can effectively improve the lung tissue pathological structure of ALI mice and effectively alleviate acute lung injury, thus confirming the synergistic effect between the components in Se@EVs-CS / HA.
[0066] Example 8: Se@EVs-CS / HA upregulates the expression of anti-inflammatory factors and antioxidant enzymes in the lung tissue of ALI mice. 1. Experimental Methods Lung tissue collected in Example 7 was used to detect the mRNA expression levels of inflammatory factors and antioxidant enzymes in the lung tissue by RT-PCR.
[0067] 2. Experimental Results RT-PCR results showed that, compared to the Ctrl group, the LPS group had increased mRNA expression levels of TNF-α, IL-1β, and IL-6, and decreased mRNA expression levels of IL-10 in lung tissue, indicating that LPS-induced ALI leads to increased levels of pro-inflammatory factors and decreased levels of anti-inflammatory factors in lung tissue. Compared to other treatment groups, Se@EVs-CS / HA downregulated the mRNA expression of TNF-α, IL-1β, and IL-6, while upregulating the mRNA expression of IL-10. Figure 11 Content a~ Figure 11 Content d) indicates that Se@EVs-CS / HA can significantly reduce the inflammatory response in the lung tissue of ALI mice and induce an anti-inflammatory response.
[0068] Compared with the Ctrl group, the mRNA expression levels of antioxidant enzymes SOD1, SOD2, and CAT in the lung tissue of mice in the LPS-induced ALI model group were significantly decreased. Among all treatment groups, Se@EVs-CS / HA showed the most significant upregulation effect on the mRNA expression of SOD1, SOD2, and CAT. Figure 12 Content a~ Figure 12 Content c).
[0069] Example 9 Macrophage polarization phenotype in Se@EVs-CS / HA reprogrammed ALI mice 1. Experimental Methods Lung tissue collected in Example 7 was embedded, sectioned, dewaxed, and subjected to graded ethanol hydration for antigen retrieval. Then, it was treated with 0.3% methanol hydrogen peroxide solution at room temperature for 15 min to inactivate endogenous peroxidase. After washing with PBS, it was blocked with 5% BSA at room temperature for 60 min. After blocking, primary antibody (F4 / 80) was added. + and CD206 +Incubate in a humidified chamber at 4°C for 24 hours, then wash sections with PBS, add the appropriate species' secondary antibody, and incubate at room temperature in the dark for 2 hours. After washing again, stain the nuclei with DAPI for 10 minutes, wash thoroughly with PBS, and mount with anti-fluorescence quenching mounting medium. Images are acquired using a confocal microscope, and observed at F4 / 80. + and CD206 + The intensity and distribution of positive signals were used to assess the relative number and distribution of macrophages in lung tissue.
[0070] 2. Experimental Results The results of double fluorescent staining showed that ( Figure 13 In each treatment group, the F4 / 80% ... + (Green fluorescence), CD206 + The highest fluorescence intensity was observed in the red fluorescence, indicating that treatment of ALI mice with Se@EVs-CS / HA effectively increased the infiltration of M2 macrophages in the lung tissue of ALI mice, which is beneficial to promoting the resolution of lung inflammation.
[0071] Those skilled in the art will readily understand that the above are merely preferred embodiments of this application and are not intended to limit this application. Any modifications, equivalent substitutions, and improvements made within the spirit and principles of this application should be included within the scope of protection of this application.
Claims
1. An extracellular vesicle containing selenium-loaded nanoparticles derived from macrophages, characterized in that, It includes extracellular vesicles derived from macrophages, and selenium nanoparticles synthesized through biomineralization encapsulated in the extracellular vesicles; the surface of the extracellular vesicles is also modified with cationic polysaccharides and anionic polysaccharides.
2. The extracellular vesicles of selenium-loaded nanoparticles derived from macrophages according to claim 1, characterized in that, The macrophages are any one of the following: macrophages derived from human peripheral blood mononuclear cells, macrophages derived from human mononuclear cell lines, macrophages derived from mouse bone marrow, and mouse mononuclear macrophage cell lines.
3. The extracellular vesicles of selenium-loaded nanoparticles derived from macrophages according to claim 1, characterized in that, The cationic polysaccharide is chitosan or its derivative.
4. The extracellular vesicles of selenium-loaded nanoparticles derived from macrophages according to claim 1, characterized in that, The anionic polysaccharide is hyaluronic acid.
5. The extracellular vesicles of selenium-loaded nanoparticles derived from macrophages according to claim 1, characterized in that, The extracellular vesicles of the selenium-loaded nanoparticles derived from macrophages have a particle size of 200~400nm.
6. A method for preparing extracellular vesicles of selenium-loaded nanoparticles derived from macrophages as described in any one of claims 1 to 5, characterized in that, Includes the following steps: S1. Macrophages were co-incubated with a culture medium containing selenium source. Selenium nanoparticles were synthesized in the macrophages through biomineralization. Then, apoptosis was induced by ultraviolet irradiation. Differential centrifugation was used to obtain macrophage-derived extracellular vesicles containing selenium nanoparticles. S2. The macrophage-derived extracellular vesicles coated with selenium nanoparticles are sequentially mixed with cationic polysaccharide solution and anionic polysaccharide solution and incubated, so that the cationic polysaccharide and anionic polysaccharide are sequentially modified onto the surface of the macrophage-derived extracellular vesicles, and the macrophage-derived selenium nanoparticle-loaded extracellular vesicles are collected.
7. The preparation method according to claim 6, characterized in that, In step S1, the selenium source is one or more of sodium selenite, sodium selenate, selenium dioxide, selenomethionine, selenocysteine, methylselenocysteine, selenourea, sodium selenosulfate, selenoacetic acid, and selenourea; and / or, The concentration of the selenium source is 0.05~0.5 mmol / L; and / or, The concentration of the macrophages was 1×10⁻⁶. 7 Cells / mL ~ 1×10 8 per mL.
8. The preparation method according to claim 6, characterized in that, In step S1, the co-incubation time is 8~12h; The differential centrifugation operation is as follows: centrifuge at 1000~2000 rpm for 5~10 min, take the supernatant and centrifuge at 12000~15000 rpm for 15~20 min, collect the precipitate, and thus obtain the macrophage-derived extracellular vesicles encapsulated with selenium nanoparticles.
9. The preparation method according to claim 6, characterized in that, In step S2, the mass ratio of the macrophage-derived extracellular vesicles coated with selenium nanoparticles to cationic polysaccharides and anionic polysaccharides is (0.5~2):(2~8):(1~4); The collection conditions are: collection with a centrifugal force of 10,000 to 12,000 rpm.
10. A medicament for treating acute lung injury, characterized in that, The drug comprises extracellular vesicles of selenium-loaded nanoparticles derived from macrophages as described in any one of claims 1 to 5.
